SCHEMBL3010740

SCHEMBL3010740

CC(C)(C)c1ccc(S(=O)(=O)N2CCN(c3nc(-c4ccc(Cl)cc4Cl)cs3)CC2)cc1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.56
HSD11B1 P28845 9/20 0.55
ALDH1A1 P00352 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
POLB P06746 2/20 0.48
KMT2A Q03164 2/20 0.47
MEN1 O00255 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
MAPT P10636 4/20 0.47
USP2 O75604 1/20 0.47
RECQL P46063 1/20 0.47
HSD17B10 Q99714 1/20 0.47
LMNA P02545 2/20 0.46
NPSR1 Q6W5P4 2/20 0.46
HTT P42858 1/20 0.46
EPHX2 P34913 1/20 0.44
GAA P10253 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3006931 0.91 AR (0.64) ARALDH1A1SMN1; SMN2L3MBTL1POLB
SCHEMBL3013101 0.89 AR (0.59) ARHSD11B1ALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL3022480 0.87 SMN1; SMN2 (0.69) ARALDH1A1SMN1; SMN2L3MBTL1POLB
SCHEMBL3012928 0.87 AR (0.59) ARALDH1A1SMN1; SMN2L3MBTL1POLB
SCHEMBL3008962 0.87 SMN1; SMN2 (0.66) HSD11B1ALDH1A1SMN1; SMN2L3MBTL1KMT2A
SCHEMBL3018002 0.86 HSD17B10 (0.58) ARHSD11B1ALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL3007611 0.86 ALDH1A1 (0.59) HSD11B1ALDH1A1SMN1; SMN2L3MBTL1POLB
SCHEMBL2997717 0.86 AR (0.60) ARHSD11B1ALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL3020212 0.86 AR (0.53) ARHSD11B1ALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL3014225 0.86 AR (0.63) ARALDH1A1SMN1; SMN2L3MBTL1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885HSD11B1 1034/4885ALDH1A1 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.